Startups
Dewpoint Therapeutics
Clinical-stage biotechnology company developing small molecules that modulate biomolecular condensates. Its ERSAi discovery platform uses AI, machine learning and experimental biology to identify relationships between condensates, disease and chemistry. Programs include a beta-catenin modulator in clinical development for gastric cancer and preclinical MYC and TDP-43 programs for cancer, ALS and related neurodegenerative diseases.
Team
Ameet NathwaniChief Executive Officer · Board Member |
Amir NashatChair of the Board of Directors |
Ann BoijaChief Scientific Officer |
Anthony HymanScientific Founder · Board Member |
Avinash PatelHead of Early Discovery |
Dean MulaHead of Finance & Accounting |
Francis CarpenterSVP, Head of Technology and Corporate Strategy |
Giuseppe CiaramellaBoard Member |
Heather HamelGeneral Counsel, Head of Corporate Affairs and Corporate Secretary |
Isaac KleinChief Development and Operating Officer |
Karl HsuClinical Development |
Mark MurckoBoard Member |
Nino JeenaHead of Financial Planning & Analysis |
Olivier BrandicourtBoard Member |
 Phil SharpChair of the Scientific Advisory Board |
Regina BarzilayBoard Member |
Richard YoungScientific Founder · Board Member |
Srinivas AkkarajuBoard Member |
Steven NeierBoard Member |